Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)

Marchetti, Cláudia; Gasparri, Maria Luisa; Ruscito, Ilary; Palaia, Innocenza; Perniola, Giorgia; Carrone, Angela; Farooqı, Ammad Ahmad; Pecorini, Francesco; Muzii, Ludovico; Panici, Pierluigi Benedetti

doi:10.1016/j.critrevonc.2015.02.001

Cited by 15 publications

(12 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent evidences emerged in tumor behavior and the dramatic improvements achieved in the treatment of these malignancies, with particular attention in tumor biology and immunobiology, [1][2][3][4][5][6][7][8] less traumatic and more aggressive surgeries, [9][10][11][12] and new target drugs, [13][14][15][16][17][18][19][20][21] have already been highlighted by the same authors elsewhere. Despite all the advances achieved in knowledge and in clinical practice, stage at diagnosis still represents the most important prognostic factor and only few patients who are diagnosed with an advanced stage disease can be healed.…”

Section: Introductionmentioning

confidence: 99%

Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Breast cancer is the most common malignancy in women worldwide, and ovarian cancer is the most lethal gynecological malignancy. Women carrying a BRCA1/2 mutation have a very high lifetime risk of developing breast and ovarian cancer. The only effective risk-reducing strategy in BRCA-mutated women is a prophylactic surgery with bilateral mastectomy and bilateral salpingo-oophorectomy. However, many women are reluctant to undergo these prophylactic surgeries due to a consequent mutilated body perception, unfulfilled family planning, and precocious menopause. In these patients, an effective screening strategy is available only for breast cancer, but it only consists in close radiological exams with a significant burden for the health system and a significant distress to the patients. No biomarkers have been shown to effectively detect breast and ovarian cancer at an early stage. MicroRNAs (miRNAs) are key regulatory molecules operating in a post-transcriptional regulation of gene expression. Aberrant expression of miRNAs has been documented in several pathological conditions, including solid tumors, suggesting their involvement in tumorigenesis. miRNAs can be detected in blood and urine and could be used as biomarkers in solid tumors. Encouraging results are emerging in gynecological malignancy as well, and suggest a different pattern of expression of miRNAs in biological fluids of breast and ovarian cancer patients as compared to healthy control. Aim of this study is to highlight the role of the urinary miRNAs which are specifically associated with cancer and to investigate their role in early diagnosis and in determining the prognosis in breast and ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…29 Moreover, clinical trials for multiple solid tumors indicated that dual inhibition of Ang-1 and -2 had more advantages than only blocking Ang-2/Tie signaling. 30,31 We found that Ang-1 and -2 were highly expressed in cervical cancer cells and downregulating Ang-1 and -2 inhibited tumor growth, suggesting that dual inhibition of Ang-1 and -2 may be a potential anti-angiogenic pharmaceutical target for the treatment of cervical cancer.…”

Section: Discussionmentioning

confidence: 90%

Cervical cancer cell–derived angiopoietins promote tumor progression

et al. 2017

View full text Add to dashboard Cite

Metastatic or recurrent cervical cancer has limited treatment options and a high rate of mortality. Although anti-vascular endothelial growth factor drugs have shown great promise as a therapeutic target for treatment of advanced cervical cancer, drug resistance and class-specific side effects negate long-term benefits. The identification of alternative anti-angiogenic factors will be critical for future drug development for advanced or recurrent cervical cancer. In this study, we found that angiopoietins and Tie receptors were highly expressed in cervical cancer cells. Tie-2 expression in tumor cells predicted poorer prognosis. Wound closure assay and Transwell assay showed that upregulated or downregulated Ang-1 and Ang-2 expression promoted or reduced cervical cancer cell lines migration and invasion, respectively. In subcutaneous xenograft models of cervical cancer, downregulation of Ang-1 and Ang-2 attenuated tumor growth. The expression of vimentin and endomucin and microvessel density were all significantly decreased in the siAng-1 group and siAng-2 group relative to the infection control group. Our data support that dual inhibition of Ang-1 and Ang-2 may be an alternative target for anti-angiogenic adjuvant therapy in advanced or recurrent cervical squamous cell cancer.

show abstract

“…Trebananib (AMG 386), is a novel peptibody which neutralizes the interaction between angiopoietins (Ang1/2) and their Tie2 receptors and thus is a promising agent targeting signaling pathways of angiogenesis in ovarian cancer [ 138 ].…”

Section: Hgfrmentioning

confidence: 99%

Recent developments in receptor tyrosine kinases targeted anticancer therapy

Raval¹,

Singh²,

Joshi³

et al. 2016

Vet World

View full text Add to dashboard Cite

Novel concepts and understanding of receptors lead to discoveries and optimization of many small molecules and antibodies as anti-cancerous drugs. Receptor tyrosine kinases (RTKs) are such a promising class of receptors under the investigation in past three decades. RTKs are one of the essential mediators of cell signaling mechanism for various cellular processes. Transformations such as overexpression, dysregulation, or mutations of RTKs may result into malignancy, and thus are an important target for anticancer therapy. Numerous subfamilies of RTKs, such as epidermal growth factor receptor, vascular endothelial growth factor receptor, fibroblast growth factor receptors, insulin-like growth factor receptor, and hepatocyte growth factor receptor, have been being investigated in recent years as target for anticancer therapy. The present review focuses several small molecules drugs as well as monoclonal antibodies targeting aforesaid subfamilies either approved or under investigation to treat the various cancers.

show abstract

Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)

Cited by 15 publications

References 55 publications

Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer

Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer

Cervical cancer cell–derived angiopoietins promote tumor progression

Recent developments in receptor tyrosine kinases targeted anticancer therapy

Contact Info

Product

Resources

About